ProCE Banner Activity


Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2022

Text Module

Review expert perspectives and insights on the most clinically relevant data for cold agglutinin disease, paroxysmal nocturnal hemoglobinuria, graft-vs-host disease, immune thrombocytopenia, and hemophilia presented at the 2022 Hematology Annual Meeting.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 23, 2023

Expiration: March 22, 2024

No longer available for credit.



Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Corey Cutler

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

David Dingli

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

Marshall Mazepa

Marshall Mazepa, MD

Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Allison Wheeler

Allison Wheeler, MD, MSCI

Associate Professor
Department of Pathology, Microbiology, and Immunology
Department of Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from






Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation



Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Program Learning Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with nonmalignant hematologic disorders
  • Evaluate new data on novel agents and therapeutic approaches for patients with nonmalignant hematologic disorders

  • Appraise how new trial findings might affect treatment of patients with nonmalignant hematologic disorders in the future


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Dianthus; researcher: Argenx, Incyte, Rigel, Sanofi, Star Therapeutics.

Corey Cutler, MD, MPH, FRCPC: consultant/advisor/speaker: CSL Behring, CTI Biopharma, Equillium, Incyte, Janssen, Jazz, Mallinckrodt, Sanofi; owner: Cimeio.

Marshall Mazepa, MD: non-CME/CE services: Sanofi.

David Dingli, MD, PhD: consultant: Alexion, Apellis, Janssen, Novartis, Sanofi, Takeda; independent contractor: Sorrento Therapeutics.

Allison Wheeler, MD, MSCI: consultant/advisor/speaker: Bayer, Bioverativ, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 23, 2023, through March 22, 2024:

1. Create an account or Login at
2. Read the target audience, learning objectives, and faculty disclosures
3. View and study the content in its entirety
4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.